It will be conducted on 60 patients having with mild to moderate degree UC divided into two groups:~Group 1 (n=30): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid).~Group 2 (n=30): Patients will receive conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid) and empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day).~The patient will be selected from the Gastroenterology and Endoscopy Unit, Internal Medicine.~. All patients will be subjected to the following:~Complete history taking.~Colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of UC.~Blood sample collection to assess:~A) Routine Laboratory tests~Complete blood picture (CBC).~Liver functions (ALT, AST, Total and Direct Bilirubin).~Kidney functions tests (Urea, serum creatinine).~C-reactive protein.~Fasting blood glucose.~Urine analysis. B) Specific Laboratory tests~1. Tumor necrosis factor alpha (TNF-α). 2. Adenosine monophosphate kinase (9AMPK). 3. Fecal calprotectin. All patients will be assessed at baseline and after 4 months of therapy for all parameters
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.